ClinicalTrials.gg
RecruitingNCT07428616STELLAR-201Updated Oct 28, 2026

A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

A Phase 2 interventional study of Zanzalintinib in Meningioma, sponsored by Exelixis. Recruiting at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Exelixis · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Updated Oct 28, 20264 sites added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 129 studies in Meningioma with a site in United States — 27 open to participants now, 39 under way, 1 of them phase 3. Meningioma · United States.

Planned enrollment
21st of 107
100 · median 30
Started
2026
with 4 others
Phase 2
46 of 129
10 open now
Primary completion
2028-02
later than 20 of 37 live
Registered
127th of 129
by date

Among the 129 studies in Meningioma with a site in United States, this one is the 21st largest by planned enrollment of the 107 interventional ones that give a count, is one of 5 that started in 2026, is one of 46 in phase 2, reaches primary completion later than 20 of the 37 other live ones, and was the 127th registered.

Meningioma

255 studies on the registry are indexed under Meningioma; 85 are open to participants now.

Browse Meningioma studies →

Open to participants now

27 of the 129 studies in Meningioma with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Meningioma studies recruiting now, 43 (65%) set no upper age limit and 9 (14%) stop at 75 or younger; 8 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 129 studies in Meningioma with a site in United States, or all of them as a file.
02

Study summary

The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.

03

Conditions studied

  • Meningioma

Keywords

  • Meningioma
  • Recurrent Meningioma
  • Progressive Meningioma
  • Atypical Meningioma
  • Anaplastic Meningioma
  • Brain
  • Zanzalintinib
  • XL092
  • Grade 1 Meningioma
  • Grade 2 Meningioma
  • Grade 3 Meningioma
  • Intracranial Neoplasms
  • Extracranial Meningioma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • confirmed World Health Organization (WHO) grade 1, 2, or 3 meningioma.
  • Developed recurrent disease or progressive disease (PD) after receiving standard therapy (for example, surgery and/or radiation) or have been deemed ineligible to receive these therapies. At least 1 prior course of meningioma-directed radiotherapy is required, if not .
  • Radiologically documented progression of any existing tumor (growth > 15% of the bidimensional enhancing tumor within the prior 6 months or appearance of new lesions (including intra and extracranial manifestations).
  • For participants treated with external beam radiation, interstitial brachytherapy, or radiosurgery, an interval ≥ 24 weeks must have elapsed from completion of therapy to initiation of treatment.
  • by RANO meningioma criteria as determined by the investigator, obtained ≤ 14 days prior to initiation of treatment.
  • performance status (KPS) ≥ 60%.
  • Demonstrate adequate organ and marrow function within 14 days of treatment initiation

Key Exclusion Criteria:

  • Prior history of hypertensive encephalopathy at any time.
  • Extracranial lesions invading major blood vessels including, but not limited to, inferior vena cava, pulmonary artery, or aorta.
  • Contraindication to magnetic resonance imaging (MRI).
  • Local therapy (surgery and/or radiation therapy) is indicated per investigator
  • Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including ) within 4 weeks or 5 half-lives, whichever is shorter, before initiation of treatment. There is no limit on prior systemic therapies
  • Prior Surgery - completed wound healing must occur prior to initiation of treatment; ≥ 8 weeks for major surgery, ≥ 7 days for minor surgery, including stereotactic .
  • The participant has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:

    • Cardiovascular disorders, including uncontrolled hypertension,
    • Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation,
    • hematuria, hematemesis, or hemoptysis of > 0.5 teaspoon (2.5 milliliters [mL]) of red blood within 12 weeks before initiation of treatment or other history of significant bleeding (eg, intracranial hemorrhage/bleeding), or
    • Other clinically significant disorders.
  • Requirement for hemodialysis or peritoneal dialysis.
  • History of solid organ or stem cell transplant.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Zanzalintinib

    Participants will receive zanzalintinib once daily (QD).

    Drug: Zanzalintinib

Interventions

  • Administered as specified in the treatment arm.

    Also known as: XL092

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) per Response Assessment in Neuro-oncology (RANO) as Assessed by Blinded Independent Central Review (BICR)

    Time frame: Up to approximately 12 months

Secondary outcomes

  1. Progression-free Survival at 6 Months (PFS-6) per RANO as Assessed by BICR and Investigator

    Time frame: Up to 6 months

  2. Duration of Response (DOR) per RANO as Assessed by BICR and Investigator

    Time frame: Up to approximately 48 months

  3. Progression-free Survival (PFS) per RANO as Assessed by BICR and Investigator

    Time frame: Up to approximately 48 months

  4. Overall Survival (OS)

    Time frame: Up to approximately 48 months

  5. Number of Participants with Treatment-emergent Adverse Events (TEAEs)

    Time frame: Up to approximately 48 months

  6. Change from Baseline in Neurologic Function as Measured by the Neurologic Assessment in Neuro-oncology (NANO) Scale Score

    Time frame: Baseline up to approximately 13 months

  7. Change from Baseline in Health-related Quality of Life (HRQoL) as Measured by the EuroQol 5-dimension 5-level Questionnaire (EQ-5D-5L) Score

    Time frame: Baseline up to approximately 13 months

07

Study locations

20 of 20 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Feb 2028, 21 months after the start.

Of 37 phase 2 interventional studies under Meningioma, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 108. This study's planned 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2026
First posted
Feb 24, 2026
StartActual
May 21, 2026
Primary completionEst.
Feb 29, 2028
CompletionEst.
Sep 30, 2029
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 1 site removed
Show 4 added (4 United States)
  • Tampa General Hospital · Tampa, United States
  • Northwestern University · Chicago, United States
  • University of California, San Francisco · San Francisco, United States
  • Mayo Clinic_Rochester · Rochester, United States
Show 1 removed
  • Mayo Clinic_Rochester · Rochester, United States
across 3 updates, Oct 6, 2026 – Oct 28, 2026
Show all 3 updates
  1. Oct 28, 2026
    1 site added, 1 site removed
    Show site
    • Mayo Clinic_Rochester · Rochester, United States
    Show 1 removed
    • Mayo Clinic_Rochester · Rochester, United States
  2. Oct 23, 2026
    1 site added
    Show site
    • University of California, San Francisco · San Francisco, United States
    + 1 other change: verification date
  3. Oct 6, 2026
    2 sites added
    Show 2 added (2 United States)
    • Tampa General Hospital · Tampa, United States
    • Northwestern University · Chicago, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07428616
Lead sponsor
Exelixis
Responsible party
Sponsor
First posted
Feb 24, 2026
Start date
May 21, 2026
Primary completion
Feb 29, 2028 (estimated)
Completion
Sep 30, 2029 (estimated)
Last update
Oct 28, 2026

Study contacts

Exelixis Clinical Trials
Contact
druginfo@exelixis.com
1-888-EXELIXIS (888-393-5494)
Backup or International
Contact
650-837-7400
Study Director
study director · Exelixis

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zanzalintinib

Start the discussion